Therapeutic Peptides intermediate
Octreotide LAR
Long-acting repeatable microsphere formulation of octreotide providing 28-day sustained somatostatin receptor agonism.
By Encyclopeptide Editorial | 1 min read
octreotide LAR somatostatin microspheres acromegaly
Chemical Identity
| Property | Value |
|---|---|
| Product Name | Sandostatin LAR |
| Active Component | Octreotide acetate |
| Dose | 10, 20, or 30 mg monthly |
| Route | IM injection |
Formulation
PLGA microspheres encapsulate octreotide for 28-day sustained release. Initial burst release followed by sustained release over 4 weeks.
Clinical Applications
- Acromegaly (first-line medical therapy)
- Neuroendocrine tumors (carcinoid syndrome)
- VIPomas
- Glucagonomas
Biological Significance
This molecule plays important roles in biological systems and has potential therapeutic applications.
References
- Encyclopeptide Database. “Octreotide LAR” monograph. encyclopeptide.com.
Test Your Knowledge
Reinforce what you learned about Octreotide LAR with interactive quizzes on Wikipept.
Take a Quiz on Wikipept